Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...
Novo Nordisk (NVO) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by March 25 Deadline
New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
AOL6d
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight ...
The Motley Fool10d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.
WRAL6d
Weight loss pill could replace injections, would be transformative for millions
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...
Morningstar7d
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...
MarketWatch25d
White House says popular weight-loss drug Ozempic subject to Medicare talks
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...